June 22, 2022

Moderna Q&A on their early data on their bivalent booster’s neutralising antibody response against omicron subvariants BA.4 and BA.5

Today, Moderna have published in a press release their top-line findings looking at neutralising antibody responses from their Omicron-containing bivalent COVID-19 vaccine against the omicron subvariants BA.4 and BA.5.

Dr Paul Burton, Moderna’s Chief Medical Officer, was available on this call to answer journalists’ questions.

Please note that was early top-line data with no paper or preprint. The data is being submitted to regulators and for peer review publication.

Speakers included:

Dr Paul Burton, Chief Medical Officer, Moderna